Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s43018-023-00634-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunotargeting of a recurrent AML-specific neoantigen.
Nat Cancer
October 2023
Université de Montréal, Montreal, Quebec, Canada.
Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas.
Biomedicines
September 2022
Department of Pediatric Hematology and Oncology, University of Tuebingen, 72076 Tuebingen, Germany.
CD19CAR T cells facilitate a transformational treatment in various relapsed and refractory aggressive B-lineage cancers. In general, encouraging response rates have been observed in B-lineage-derived non-Hodgkin's lymphomas treated with CD19CAR T cells. The major cause of death in heavily pretreated NHL patients is lymphoma progression and lymphoma recurrence.
View Article and Find Full Text PDFIncreased Serum Level of Interleukin-10 Predicts Poor Survival and Early Recurrence in Patients With Peripheral T-Cell Lymphomas.
Front Oncol
October 2020
Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Peripheral T cell lymphoma (PTCL) is an alloplasm group of aggressive and lymphoproliferative tumors with heterogeneous morphological changes of mature T cell immunophenotype. It has multiple subtypes and most of them have poor prognosis. Interleukin 10 (IL-10) is one kind of multi-cell-derived and multifunctional cytokine.
View Article and Find Full Text PDFBreast cancer stem cell antigens as targets for immunotherapy.
Semin Immunol
February 2020
Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy. Electronic address:
The great success of immunotherapy is paving the way for a new era in cancer treatment and is driving major improvements in the therapy of patients suffering from a range of solid tumors. However, the choice of the appropriate tumor antigens to be targeted with cancer vaccines and T-cell therapies is still a challenge. Most antigens targeted so far have been identified on the tumor bulk and are expressed on differentiated cancer cells.
View Article and Find Full Text PDFCancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source.
Prog Mol Biol Transl Sci
April 2020
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
Despite recent advances in diagnosis and therapy having improved cancer outcome, many patients still do not respond to treatments, resulting in the progression or relapse of the disease, eventually impairing survival expectations. The limited efficacy of therapy is often attributable to its inability to affect cancer stem cells (CSCs), a small population of cells resistant to current radio- and chemo-therapies. CSCs are characterized by self-renewal and tumor-initiating capabilities, and function as a reservoir for the local and distant recurrence of the disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!